PRESS RELEASE

A&C MAKE NATIONAL HEADLINES IN IRELAND DUE TO ITS CONTRIBUTION TO LEADING SARS-CoV-2 COVID-19 VACCINE CANDIDATE

A&C Bio Buffer Ltd recently made national headlines on the Irish Examiner’s broadsheet on COVID-19 projects in Ireland for its crucial role in the development of one of the current leading SARS-CoV-2 (COVID-19) vaccine candidates. A&C Bio Buffer Ltd provided critical raw materials essential for the mRNA vaccine manufacturing project led by a well-known German vaccine developer. A&C Bio Buffer Ltd is member of the A&C Group, a Canadian-owned pharmaceutical supply company which has its headquarters and two GMP manufacturing facilities in Montreal, Canada.

A&C’s Irish GMP manufacturing plant was approached by the German biotech company and was asked to develop three proprietary GMP buffers and WFI (Water for Injection) — essential materials in their experimental mRNA COVID-19 vaccine manufacturing process. Due to the urgency of the project, A&C was required to develop, manufacture and deliver the GMP materials in four weeks, which is approximately five times faster than the industry norm for GMP buffer development projects.

A&C accepted the almost impossible challenge, putting on extra night and weekend shifts in its GMP manufacturing facility in Ireland. To complete the difficult task on time for their German client, A&C also utilized personnel and resources from their other two GMP manufacturing sites located in North America. A&C’s flexibility and responsiveness have enabled them to complete process development from lab scale up to full commercial material and accelerate the timeline. This has allowed the human clinical trials to take place as planned and put the German firm in the front running for the first COVID-19 vaccine, which has now gone to phase 2b/3 safety and efficacy study.

“A&C are honored to be part of this potential life-saving COVID-19 vaccine project. We are extremely proud of the huge work that our staff have put in to meet the short timeline presented to us, and hopefully this vaccine candidate will get approval in the near future.” stated Gearoid O’Rourke, Sales and Marketing Director for A&C.

A&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of APIs with offices and GMP production facilities in North America and Ireland. The A&C Irish plant is dedicated to GMP manufacturing of biological buffers, process solutions, cleaning solutions, chemical blends and WFI (water for injection). The A&C Group has been servicing the life sciences industry since 1966, is a service-driven organisation finding unique solutions to customers’ GMP challenges and proud member of BIOTECanada.